Company Overview of Tris Pharma, Inc.
Tris Pharma, Inc., a specialty pharmaceutical company, engages in research, development, and manufacture of over-the-counter, Rx branded products, and specialty generic products in the United States. The company develops extended release formulations for products intended for children, elderly, and adults having difficulty swallowing pills and requiring multi-dose treatment. Its products pipeline includes products for various disease indications, such as cough and cold, pain management, and neurological disorders. The company also offers specialty generic products in immediate and extended release versions. Tris Pharma, Inc. offers its products in various dosage forms, such as package powder...
2033 Route 130
Brunswick Business Park
Monmouth Junction, NJ 08852
Founded in 2000
Key Executives for Tris Pharma, Inc.
Director of Finance and Controller
Vice President of Operations
President of Generic Pharmaceuticals Business
Chief Scientific Officer and Executive Vice President of R&D Including Regulatory Affairs
Compensation as of Fiscal Year 2014.
Tris Pharma, Inc. Key Developments
Vernalis plc and Tris Pharma, Inc. Announce New Drug Application
Jun 30 14
Vernalis plc and Tris Pharma, Inc. announced that a new drug application has been submitted to the U.S. Food and Drug Administration for Tuzistra XR (CCP-01), for the acute treatment of cough cold. The FDA has 60 days in which to confirm whether the NDA is accepted for full review, and on receipt of this confirmation a milestone payment to Tris is triggered. CCP-01 represents the first product within this pipeline to reach NDA stage.
Tris Pharma Announces Executive Appointments
Jun 26 14
Tris Pharma announced two key additions to its' executive team: Sally A. Berry, MD, PhD will join as chief medical officer and Norma Cappetti will join as vice president of regulatory affairs. Prior to joining Tris, most recently Berry was working with Pfizer, and prior to that was chief medical officer of NextWave Pharmaceuticals. Ms. Cappetti joins Tris with over 35 years of experience in the pharmaceutical industry including 25 years in managing and leading regulatory affairs. Ms. Cappetti has both international and domestic regulatory experience and her therapeutic areas of experience include but are not limited to CNS, Respiratory, Cardiovascular and Endocrinology.
Tris Pharma Announces Management Changes
Apr 1 14
Tris Pharma announced several key management changes, including the new appointment of Mr. Stephen J. Kovary to the position of Vice President of Operations. Mr. Kovary brings three decades of pharmaceutical experience in the areas of manufacturing, process improvement, facilities, engineering, plant and systems management. Prior to joining Tris, Kovary held senior positions at Daiichi Sankyo, Lannett, Purdue Pharmaceuticals, Abbott, Parke-Davis and BMS. As part of the expansion of Tris' management team and focus on operational excellence, Gerry Cocuzza, Tris' recently appointed Vice President of Engineering will report to Mr. Kovary. Tris currently operates out of its combined 130,000 sq. ft. facilities located on its 17 acre campus in Monmouth Junction, NJ as well as a recently acquired warehouse facility in Cranbury, NJ. Tris continues to expand its management team as well as to invest heavily in research and development and technical operations to meet the increasing demands of its branded prescription and OTC partners for its approved and new products under development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|